BIOCON LTD. - 532523 - Announcement Under Regulation 30
Investor Meeting22-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find attached transcript of earnings call held on 10.11.202320-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pls find enclosed details of meeting conducted with Investor20-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pls find enclosed Investor Presentation - Q2 FY24.17-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of schedule of meeting with Analyst/ Institutional Investor17-11-2023
Biocon gains on UK health agency's marketing nod to subsidiary for ophthalmic biosimilar
Earlier in this month, Eris Lifesciences has signed a definitive agreement with Biocon Biologics to acquire its Branded Formulations' India (BFI) business units of nephrology and dermatology.15-11-2023
Biocon: Should you buy the stock after Q2 results? Here's what brokerages say
Domestic brokerages have mixed views on Biocon's stock after its Q2 FY24 earnings. While Kotak Institutional Equities maintained its 'Reduce' rating on the stock, JM Financial continued its 'Buy' rating on Biocon.13-11-2023
Biocon 3% lower despite 2x rise in Q2 net profit
Analysts at Motilal Oswal have reiterated their neutral call with a target price of Rs 220 as the financial results missed their estimates.13-11-2023
Biocon Results Earnings Call for Q2FY24
Conference Call with Biocon Ltd. Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: Kiran Mazumdar Shaw and senior team12-11-2023